NYXH Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.810

Open

2.785

VWAP

2.79

Vol

18.25K

Mkt Cap

121.82M

Low

2.760

Amount

50.87K

EV/EBITDA(TTM)

--

Total Shares

43.66M

EV

100.17M

EV/OCF(TTM)

79.13

P/S(TTM)

--

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Show More

Events Timeline

(ET)

2026-03-19

16:30:00

Nyxoah Reports Q4 Revenue of €5.64M

2026-03-19

16:30:00

Company Expects U.S. Net Revenue to Grow 25% in Q1 2026

2026-02-18 (ET)

2026-02-18

16:30:00

Nyxoah Signs MoU with UAE Hospital for Genio Therapy

2026-01-21 (ET)

2026-01-21

16:30:00

Nyxoah Invests in Belgium to Expand Manufacturing Capacity

2026-01-12 (ET)

2026-01-12

16:20:00

Nyxoah Reports Preliminary FY25 Gross Revenue of EUR 11M

News

Yahoo Finance

03-20Yahoo Finance

Nyxoah Secures FDA Approval and Successful U.S. Launch

NASDAQ.COM

03-20NASDAQ.COM

Nyxoah (NYXH) Q4 2025 Earnings Call Transcript

seekingalpha

03-19seekingalpha

Nyxoah Reports Strong Q4 Earnings with 330.8% Revenue Growth

Newsfilter

02-27Newsfilter

Nyxoah Receives Transparency Notification from Robert Taub

Newsfilter

02-25Newsfilter

Nyxoah SA Discloses Voting Rights and Share Information

seekingalpha

01-14seekingalpha

Nyxoah (NYXH) Projects 25% Revenue Growth for Q1 2026

5 Analyst Rating

Wall Street analysts forecast NYXH stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.82

Averages

10.41

High

13.00

Current: 0.000

Low

5.82

Averages

10.41

High

13.00

Baird

David Rescott

Neutral

downgrade

AI Analysis

2026-03-23

Reason

Baird

David Rescott

Price Target

AI Analysis

2026-03-23

downgrade

Neutral

Reason

Baird analyst David Rescott lowered the firm's price target on Nyxoah to $4.62 from $5.87 and keeps a Neutral rating on the shares. The firm updatedits mdel as its U.S. rollout gains traction but still in its early days.

Stifel

Buy

downgrade

$11 -> $10

2026-03-20

Reason

Stifel

Price Target

$11 -> $10

2026-03-20

downgrade

Buy

Reason

Stifel lowered the firm's price target on Nyxoah to $10 from $11 and keeps a Buy rating on the shares. The firm, which updated its model for "some moving parts, still reflects an equity raise in Q3 on the heels of ACCCESS data being reported.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NYXH

Unlock Now

Valuation Metrics

The current forward P/E ratio for Nyxoah SA (NYXH.O) is -1.80, compared to its 5-year average forward P/E of -5.80. For a more detailed relative valuation and DCF analysis to assess Nyxoah SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.80

Current PE

-1.80

Overvalued PE

-0.50

Undervalued PE

-11.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-4.88

Current EV/EBITDA

-1.69

Overvalued EV/EBITDA

-0.56

Undervalued EV/EBITDA

-9.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

35.34

Current PS

7.36

Overvalued PS

66.16

Undervalued PS

4.52

Financials

AI Analysis

Annual

Quarterly

Whales Holding NYXH

Trading Trends

People Also Watch

Frequently Asked Questions

What is Nyxoah SA (NYXH) stock price today?

The current price of NYXH is 2.79 USD — it has decreased -1.06

What is Nyxoah SA (NYXH)'s business?

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

What is the price predicton of NYXH Stock?

Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is10.41 USD with a low forecast of 5.82 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nyxoah SA (NYXH)'s revenue for the last quarter?

Nyxoah SA revenue for the last quarter amounts to 5.64M USD, increased 346.87

What is Nyxoah SA (NYXH)'s earnings per share (EPS) for the last quarter?

Nyxoah SA. EPS for the last quarter amounts to USD, decreased -100.00

How many employees does Nyxoah SA (NYXH). have?

Nyxoah SA (NYXH) has 147 emplpoyees as of March 31 2026.

What is Nyxoah SA (NYXH) market cap?

Today NYXH has the market capitalization of 121.82M USD.